Pharmaceutical forecasting often sparks debate: Should forecasts be based on epidemiology or sales data?
Some argue that every forecast must start with epidemiology, because unless you start with epidemiology, you might miss opportunities for market expansion and greater sales. While others claim that sales-based forecasting provides a more accurate and reliable approach.
Gary Johnson and Sam Johnson’s answer? Neither approach is inherently better. In their The Pharma Forecasting Course, they teach a practical framework that blends both methods to ensure the approach is right for your specific product.
Epi-based forecasting builds projections from the ground up, starting with:
Sales-based forecasting starts with existing market sales data and analyses:
Rather than choosing one method over the other, Gary and Sam recommend a progressive approach that anchors forecasts at the most stable level in the epi cascade.
The result? Once you master these principles, you will never feel the need to argue for epi-based forecasts or sales-based forecasts. You will understand just how they both have their place.
The five techniques most worth knowing, whichever approach you start from:→ The 5 most useful sales forecasting techniques for pharmaceuticals |
Continue your learning from Gary and Sam
If you’d like to learn more from Gary and Sam, CELforPharma also offers a 2-day, hands-on course where you'll:
Don’t miss the latest insights from our expert faculty
Subscribe to our newsletter to: